Explore the latest news and publications from Latigo Biotherapeutics
Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth
July 22, 2024
Farzan brings more than two decades’ leadership experience with a strong track record in fundraising…
Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action
February 23, 2024
Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders.
Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines
February 14, 2024
Potential best-in-class lead program targets Nav1.8, a validated human target for pain.